The ability to visualize reporter gene expression in vivo has revolutionized all facets of biological investigation and none more so than imaging applications in oncology. Near-infrared reporter gene imaging may facilitate more accurate evaluation of chemotherapeutic response in preclinical models of orthotopic and metastatic cancers. We report the development of a cell permeable, quenched cyanine probe (CytoCy5S), which is reduced by Escherichia coli nitroreductase (NTR) resulting in a near-infrared fluorescent product. Time-domain molecular imaging of NTR/CytoCy5S reporter platform permitted non-invasive monitoring of disease progression in orthotopic xenografts of disseminated leukemia, lung and metastatic breast cancer. This methodology facilitated therapeutic evaluation of nitroreductase gene-directed enzymatic prodrug therapy with conventional metronidazole antibiotics. These studies demonstrate NTR/CytoCy5S as a near-infrared gene reporter system with broad preclinical and prospective clinical applications within imaging, and gene therapy, of cancer.
Introduction
Non-invasive imaging, permitting spatio-temporal monitoring of both disease progression and therapeutic efficacy (1), has had a major impact upon human drug development (2) . In particular, optical imaging of fluorescent and bioluminescent reporters has emerged as one of the most important preclinical imaging modalities, with considerable developments in sensitive instrumentation, e.g. time-domain optical imaging (3), contributing to its success. The relative simplicity of optical hardware, ease of use and high-throughput potential has rendered optical imaging as an inexpensive modality accessible to both academic and industrial environments alike.
While reporter genes remain the cornerstone of the optical approach, an ever-expanding palette of targeted and activatable probes, exploiting the near infrared spectrum of light, enable a more complete investigation of disease pathology in situ (4) .
Anticancer drug screening in subcutaneous tumor models is neither representative of human cancer nor predictive of clinical success (5) . A consequent paradigm shift toward drug evaluation in more clinically relevant orthotopic and metastatic models has placed a greater emphasis upon imaging cancer cells in dense parenchymatous organs, demanding sensitive, deep tissue imaging.
However, the major caveats of visualizing fluorescent proteins for this application has been autofluorescence and significant attenuation of both their excitation and emitted light in mammalian tissue by hemoglobin. While use of time-domain optical imaging can delineate autofluorescence from fluorescent protein fluorescence on the basis of fluorescence lifetime (3, 6) , significant efforts have been placed on development of far-red shifted fluorescent proteins that might exploit the farred and near infrared window (approximately 630 -900 nm) where hemoglobin absorption is minimal (7) (8) (9) (10) (11) . Bioluminescence imaging, requiring no excitation source, has proven to be one of the most sensitive platforms for small animal imaging (12) . However, bioluminescence emission maxima are still < 620 nm which in addition to significant scattering of bioluminescent photons, limit spatial resolution and detection at depth.
Nitroreductase (NTR), a flavoprotein which reduces nitroaromatic prodrugs in the presence of NADPH or NADH to highly toxic metabolites, has found clinical application as a prodrug therapeutic strategy in cancer (13) . Subsequently, a number of quenched fluorogenic probes have been designed as substrates for NTR (14) (15) (16) (17) (18) , and pilot studies probing their utility in NTR mediated prodrug therapy have been performed (18) . These recent developments suggest that NTR and suitable quenched near-infrared substrate may be exploited as the basis for a reporter gene based in vivo optical imaging platform.
Here we present NTR reporter gene imaging as a method for visualization of disseminated, orthotopic and metastatic cancer in vivo, employing CytoCy5S as a quenched, near infrared substrate. Synthetic methods of cyanine based NTR substrate development; characterization and mechanism of NTR reduction are described for CytoCy5S. In our method we adopted time-domain imaging, which provides greater sensitivity and significantly higher spatial resolution and detection at depth as compared with epi-illumination imaging (19, 20) . Time 
General animal care
All experiments were approved by The Norwegian Animal Research Authority and conducted 
NCI-H460
NTR+Luc+GFP+ cells were suspended in 20 μl 1X PBS with 25% matrigel for intrapulmonary injection. 1x10 6 
MDA-MB-231
NTR+Luc+GFP+ cells were suspended in 50 μl 1X PBS with 25% matrigel for intramammary injection. Mice treated with metronidazole were given 50 mg/kg intravenously twice daily when tumors reached 100-150 mm 3 . All cell suspensions were injected with a 28 G syringe. Inoculated animals were monitored closely for signs of advancing disease such as weight loss, ruffled fur and lethargy, in general. Mice were sacrificed according to institutional guidelines.
Time-Domain optical imaging
GFP and bioluminescence images were acquired as previously described (3, 
Histology
Organ or tumor samples collected following euthanasia were transferred to a tube containing 4%
formalin for paraffin-embedding, cryosectioning and subsequent immunohistochemistry of the samples. Sections were stained with hematoxylin and eosin (H&E) and results were analyzed by standard light microscopy (Olympus BX51, Olympus America Inc., Center Valley, PA).
Statistics
In cell viability and proliferation assays, triplicates were analyzed for each sample, and results given as means +/-standard error of the mean (SEM). Statistical significance of differences in averages between treatment groups in vitro and in vivo was determined using a two-tailed Student t test (GraphPad Prism ® 5.0, GraphPad Software, La Jolla, CA). For all statistical analysis, p < 0.05 was considered significant. 
Results

Synthesis and Characterization of NTR activated fluorescent probe.
Nitroreductase catalyses the reduction of nitro-aryl groups to the corresponding hydroxylamine, providing the basis of a gene directed enzymatic prodrug therapy (13) . We postulated that introduction of an electron withdrawing dinitrophenyl moiety into the far-red chromophore Cy5 would effectively quench its fluorescence, and upon intracellular enzymatic reduction by NTR, yield a near-infrared fluorescent product providing the basis of an NTR based reporter gene platform ( Supplementary Fig. 1A , B and Supplementary Fig. 2A, B) . Thus, introduction of dinitroaryl-and squarate functionality into the Cy5 chromophore yielded CytoCy5S
( Supplementary Fig. 1A ), a proposed cell permeable substrate for NTR (26) . LC-MS analysis of CytoCy5S showed a peak at 6.32 min using detection at 630 nm, which upon initial incubation with NTR in the presence of β-NADH and β-NADPH resulted in two additional peaks with retention times of 3.08 and 1.42 minutes respectively (Supplementary Fig. 1C ). MS analysis revealed the 3.08 min product resultant of two ions with m/z of 677 and 675, consistent with the mono hydroxylamine and the mono nitroso reduction products, respectively. Analysis of the peak appearing at 1.42 minutes suggests reduction of both nitro groups to the corresponding hydroxylamines, giving an m/z of 663 for the protonated species (Supplementary Fig. 1C ). These data are consistent with an overall reduction mechanism of CytoCy5S to the dihydroxyl-product via nitroso intermediates (Supplementary Fig. 1B ). After 48 minutes reaction time, only minor amounts of both starting material and the mono-reduction products could be detected (Supplementary Fig.   1D ). Spectrophotometric analysis of the final reduction product revealed excitation and emission maxima of 631 and 688 nm, respectively ( Supplementary Fig. 1E ), and NTR dependent increase in fluorescence in enzymatic assays (Supplementary Fig. 1F) . Furthermore, kinetic analysis demonstrated a rapid fluorescence induction upon addition of CytoCy5S substrate to NTR (Supplementary Fig. 1G ). 
In vitro evaluation of CytoCy5S in NTR expressing cell lines.
Having demonstrated CytoCy5S as a substrate for NTR resulting in a highly fluorescent nearinfrared product, we retrovirally transduced a diverse array of cancer cells lines to explore its cell permeability and application as a cellular gene reporter assay. Accordingly, the cell lines NB4 (human acute promyelocytic leukemia), IPC-81 (rat acute myeloid leukemia), NCI-H460
Luc+
(human large cell lung carcinoma) and MDA-MB-231
Luc+ (human breast carcinoma) were retrovirally transduced with the tTA dependent L149 plasmid expressing both green fluorescent protein (GFP) and NTR, and tTA plasmids (Supplementary Fig. 2A , cell number and fluorescence intensity were observed and imaging at depths of 6-8 mm was achievable with 0.1 -1x10 6 cells ( Supplementary Fig. 2G, H) .
Time domain imaging of NTR/CytoCy5S fluorescence.
We CytoCy5S (Fig. 1A) . Fluorescence was noted in all animals, however the distribution of fluorescence lifetimes observed in the animals differed in mice bearing NTR + cells (Fig. 1B) as previously noted at this time point (Supplementary Fig. 3B ). While all control groups demonstrated distributions with multiple fluorescence lifetimes at this timpoint, only one predominant lifetime (peak of 1.2 ns) was evident in mice bearing NTR positive tumors. Exploiting the differences in fluorescence lifetime distributions between control and NTR positive tumors (Fig. 1C) , fluorescence lifetime gating (1.0 -1.3 ns) was employed to identify only those pixels exhibiting NTR/CytoCy5S lifetime, and used to generate gated fluorescence intensity maps of scanned mice (Fig. 1D ). Subsequently all mice were imaged 30-60 minutes post CytoCy5S injection and this gating strategy was employed in all ensuing work described here.
Longitudinal NTR/CytoCy5S imaging of disseminated and metastatic disease progression in vivo.
Having (Fig. 2D) . Leukemia was first evident after 17-24 days employing GFP gated fluorescence imaging in the same mice (Fig. 2C) .
IPC-81
WT demonstrated minimal NTR/CytoCy5S fluorescence (Fig. 2B, D) . Ex vivo imaging and HE staining of bone marrow samples from the femur and sterna of mice confirmed leukemia (Fig. 2E) .
Similarly, NTR/CytoCy5S gated images of NB4 NTR+GFP+ mice revealed earlier detection of leukemia, particularly in the spines and femurs, than respective GFP gated images at day 14 and more extensive disease patterns at day 18 (Fig. 2F) . In vivo tumors were confirmed by ex vivo imaging and histology (Fig. 2G) .
NCI-H460
NTR+Luc+GFP+ cells, expressing NTR, GFP and luciferase, were injected orthotopically into the left lung parenchyma of NSG mice (n = 5) and imaged on days 5, 8 and 14
for NTR/CytoCy5S fluorescence (Fig. 3A, F) . Bioluminescence imaging and T 1 -weighted FLASH MRI confirmed tumor placement (example in Fig. 3B, C) . Day 5 and 8 NTR/CytoCy5S gated fluorescence images were comparable to acquired bioluminescence images. Six days later both bioluminescence and NTR/CytoCy5S gated fluorescence images revealed extensive pulmonary metastasis in dorsal and ventral aspects. Necropsy of the mice and ex vivo imaging verified extensive lung metastasis (Fig. 3D, E) , which was confirmed histologically (Fig. 3F, G) .
Encouragingly NTR/CytoCy5S gated dorsal images demonstrated definitive detection of a pulmonary tumor on day 5, which was consistent with MRI imaging, bioluminescence and primary tumor location at later time points. These results suggest a role for NTR/CytoCy5S in multimodal imaging applications.
Finally, we investigated NTR/CytoCy5S gated imaging of the MDA-MB-231
NTR+Luc+GFP metastatic mammary carcinoma model (Fig. 4) . 1x10 6 cells were injected orthotopically into the mammary fat pad of NSG mice (n = 4) and NTR/CytoCy5S gated fluorescence images acquired on a weekly basis. Previously, axial lymph node metastasis has been formerly demonstrated by in vivo optical imaging of the MDA-MB-231 orthotopic breast cancer model (27, 28) . NTR/CytoCy5S gated fluorescence images revealed progressive primary tumor fluorescence up to week 7 ( Fig. 4C) with initial axial lymph node metastasis at week 8 (see arrow Fig. 4A ). Detection of additional metastasis in this region was observed by week 9 (see inset). At week 12, multiple tumors along the draining lymphatic vessel were noted and a further distal auxiliary lymphatic metastasis.
Interestingly fluorescence was also observed at the liver with a faint area of fluorescence in the upper thorax (Fig. 4B) . Ex vivo imaging following necropsy revealed fluorescence associated with 
primary tumor section, several lymph node tumors along the draining lymphatic vessel, in addition to liver fluorescence and small foci in the lungs (Fig. 4D, E) . Microscopic examination of histology sections from these organs confirmed lymph and liver metastasis (Fig. 4F) .
Gene-directed-enzyme-prodrug therapy evaluation with NTR/CytoCy5S.
NTR is typically employed as the activating enzyme in the gene-directed-enzyme-prodrug therapy (GDEPT) approach to cancer chemotherapy. We therefore investigated the use of the NTR/CytoCy5S platform for active imaging of GDEPT (Fig. 5) . The nitro-imidazole, metronidazole (MTZ, Fig. 5A ) has previously been described as an NTR substrate in; GDEPT therapeutic approaches (29) , and conditional cell ablation in Zebrafish (30) superiority of the NTR/CytoCy5S methodology compared with green fluorescent protein (Fig. 2) and the possibility for multimodal imaging with NTR/CytoCy5S and fluorescent proteins.
A caveat to the NTR reporter platform is the necessity of a fluorogenic substrate such as CytoCy5S. However, substrate injection has not prevented the luciferases in becoming the most commonly employed preclinical optical reporter gene (12, 35) . Furthermore, the rapid induction of fluorescence and consistency of the NTR/CytoCy5S signal over several hours ( Supplementary Fig.   3 ) makes this imaging platform very attractive for raster scanning imaging techniques, which typically require long timeframes of 5 -20 minutes to acquire whole body images of a single mouse. Undoubtedly a significant benefit of the NTR/CytoCy5S platform as demonstrated here has been the sensitivity of the imaging technique to detect disseminated and metastatic cancer cells in organs of high blood volume. Here we have verified the sensitivity of the NTR/CytoCy5S imaging platform to detect metastasis in the liver (Fig. 4 ) in addition to leukemia in bone marrow (Fig. 2) confirmed by ex vivo imaging and histology. 
